|UCB SA -- USA Stock|| |
USD 42.47 1.18 2.86%
Non-Executive Chairman of the Board
Mr. Gerhard N. Mayr has served as NonExecutive Chairman of the Board of U C B S.A. since May 2012. He served as NonExecutive Independent Director of the Company between June 14, 2005 and May 2012. He received a Master degree in Chemical Engineering from the Swiss Federal Institute of Technology in 1969, and a MBA degree from Stanford University in 1972. In March 2004, he retired as Executive Vice President of pharmaceutical operations at Eli Lilly Company after 32 years of service
Age: 68 Chairman Since 2012
32 2 559 99 99 http://www.ucb-group.com
Mayr is Member of the Board of Lonza Group Ltd ., Member of the Board of the Vienna Science, Research and Technology Foundation and Member of the Board of Project Hope, United States . He is Member of the circle of patrons of INSEAD Business School . He was previously Member of the board of Alcon, Inc
The company has return on total asset (ROA)
of 5.76 %
which means that it generated profit of $5.76 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 13.02 %
meaning that it generated $13.02 on every $100 dollars invested by stockholders.
The company has accumulated 1.92 B in total debt with debt to equity ratio (D/E) of 28.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.09 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.
UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA (UCBJY) is traded on OTC Market in USA. It is located in Allée de la Recherche, Brussels, and employs 7,643 people.